SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Castlight Health, Inc. (NYSE:CSLT), a
leading health benefits platform provider, today announced results for its second quarter ended June 30, 2018.
"We've seen strong validation over the last two quarters that our health navigation solution is penetrating the market
efficiently, which demonstrates the strategic value to us of our platform and channel collaborations," said John Doyle, chief executive officer of Castlight Health. "Based on these results, we will increase our focus
on adding new channel partners and align our costs accordingly. We will reduce operating expenses by 10 to 15 percent, which will
position us to break even beginning in Q4, while continuing to make the critical platform investments needed to lead the health
navigation market."
Financial performance for the three months ended June 30, 2018 compared to the three months ended June 30, 2017
includes:
- GAAP total revenue of $37.8 million, representing an increase of 16%
- GAAP gross margin of 58.4%, compared to 62.2%
- Non-GAAP gross margin of 62.2% compared to 67.4%
- GAAP operating loss of $14.1 million, compared to a loss of $17.6
million
- Non-GAAP operating loss of $6.9 million, compared to a loss of $8.7
million
- GAAP net loss per basic and diluted share of $0.10, compared to a net loss per basic and
diluted share of $0.09
- Non-GAAP net loss per basic and diluted share of $0.05, compared to a net loss per basic and
diluted share of $0.07
- Cash used in operations of $1.1 million, compared to $4.1
million
Total cash, cash equivalents and marketable securities was $74.5 million as of June 30,
2018.
A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An
explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Restructuring Program
Today, the Company is announcing a restructuring program to align its operations with its evolving business
needs. This is also due, in part, to the recent unexpected churn of a large customer. Under this program, the
Company intends to reduce operating expenses by 10 to 15 percent. The actions associated with this program are
expected to be largely completed by September 30, 2018. The Company expects to take a restructuring charge in the third
quarter of 2018, which will be excluded from its full year 2018 non-GAAP operating loss and non-GAAP net loss per share
calculation.
Business Outlook
The Company is reiterating its previously-issued 2018 outlook. For the full year 2018, the Company expects:
- GAAP revenue in the range of $150 million to $155 million
- Non-GAAP operating loss in the range of $15 million to $20
million
- Non-GAAP net loss per share of approximately $0.11 to $0.15
based on approximately 137 million to 138 million shares
Quarterly Conference Call
Castlight Health senior management will host a conference call to discuss its second quarter 2018 results and business outlook
today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the
conference call, together with detailed financial information, can be accessed through the company's Investor Relations website
at http://ir.castlighthealth.com. An archive of the
webcast can also be accessed through the same link. The live conference call can be accessed by dialing (866) 393-4306 and the
replay will be available for one week at (855) 859-2056. The conference ID number for the live call and replay is
3899475.
About Castlight Health
Castlight is on a mission to make it as easy as humanly possible to navigate healthcare and live happier, healthier, more
productive lives. Our health navigation platform connects with hundreds of health vendors, benefits resources, and plan
designs, giving rise to the world's first comprehensive app for all health needs. We guide individuals - based on their unique
profile - to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care.
In doing so, we help companies regain control over rising healthcare costs and get more value from their benefits investments.
Castlight revolutionized the healthcare sector with the introduction of data-driven price transparency tools in 2008 and the
first consumer-grade wellbeing platform in 2012. Today, Castlight serves as the health navigation platform for millions of people
and is a trusted partner to many of the largest employers in the world.
For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn
and Like us on Facebook.
Non-GAAP Financial Measures
To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles
(GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance,
including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP other income, net,
non-GAAP net loss and non-GAAP net loss per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP
operating loss, non-GAAP other income, net and non-GAAP net loss exclude stock-based compensation, litigation settlement,
amortization of intangibles, amortization of internal-use software, lease exit and related charges, changes in fair value of
contingent consideration liability, restructuring charges and charges related to the acquisition of Jiff and the associated tax
impact of these items, where applicable.
We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate
the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help
enhance overall understanding of the company's historical financial performance.
We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure,
except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2018 to
comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation
expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP
operating loss. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of
internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such
guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our
inability to project the cost or scope of internally produced software.
These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures
prepared in accordance with GAAP.
Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies,
and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial
information in its entirety and not rely on a single financial measure.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding Castlight Health's 2018 full year projections, success of our
strategy, impact of the restructuring program and our expectations for our future business and financial performance. Statements
including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the
future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as
assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those
expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight
Health's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this
press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no
obligation to update these forward-looking statements.
Copyright 2018 Castlight Health, Inc. Castlight Health ® is the registered trademark of Castlight Health,
Inc. Other company and product names may be trademarks of the respective companies with which they are associated.
|
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
|
|
|
As of
|
|
June 30,
2018
|
|
December 31,
2017
|
|
|
|
(as adjusted)(1)
|
|
Assets
|
|
|
|
|
Current assets:
|
|
|
|
|
Cash and cash equivalents
|
$
|
44,642
|
|
|
$
|
61,319
|
|
|
Marketable securities
|
29,833
|
|
|
32,025
|
|
|
Accounts receivable and other, net
|
28,184
|
|
|
21,933
|
|
|
Prepaid expenses and other current assets
|
5,742
|
|
|
3,991
|
|
|
Total current assets
|
108,401
|
|
|
119,268
|
|
|
Property and equipment, net
|
5,247
|
|
|
5,263
|
|
|
Restricted cash, non-current
|
1,325
|
|
|
1,325
|
|
|
Deferred commissions
|
24,691
|
|
|
27,512
|
|
|
Deferred professional service costs
|
11,855
|
|
|
12,480
|
|
|
Intangible assets, net
|
18,144
|
|
|
20,253
|
|
|
Goodwill
|
91,785
|
|
|
91,785
|
|
|
Other assets
|
2,141
|
|
|
1,997
|
|
|
Total assets
|
$
|
263,589
|
|
|
$
|
279,883
|
|
|
Liabilities and stockholders' equity
|
|
|
|
|
Current liabilities:
|
|
|
|
|
Accounts payable
|
$
|
4,619
|
|
|
$
|
3,907
|
|
|
Accrued expenses and other current liabilities
|
17,829
|
|
|
13,178
|
|
|
Accrued compensation
|
9,530
|
|
|
13,941
|
|
|
Deferred revenue
|
26,509
|
|
|
25,985
|
|
|
Total current liabilities
|
58,487
|
|
|
57,011
|
|
|
Deferred revenue, non-current
|
2,723
|
|
|
4,457
|
|
|
Debt, non-current
|
4,183
|
|
|
4,958
|
|
|
Other liabilities, non-current
|
2,964
|
|
|
1,900
|
|
|
Total liabilities
|
68,357
|
|
|
68,326
|
|
|
Stockholders' equity
|
195,232
|
|
|
211,557
|
|
|
Total liabilities and stockholders' equity
|
$
|
263,589
|
|
|
$
|
279,883
|
|
|
_______________
|
|
(1)
|
Prior-period information has been adjusted for the adoption of ASU No.
2014-09, Revenue from Contracts with Customers (ASC 606), which we adopted in the first quarter of
2018.
|
|
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
|
|
|
(as adjusted)(1)
|
|
|
|
(as adjusted)(1)
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Subscription
|
$
|
34,802
|
|
|
$
|
30,382
|
|
|
$
|
67,791
|
|
|
$
|
56,279
|
|
|
Professional services and other
|
2,982
|
|
|
2,250
|
|
|
6,472
|
|
|
4,056
|
|
|
Total revenue, net
|
37,784
|
|
|
32,632
|
|
|
74,263
|
|
|
60,335
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
Cost of subscription(2)
|
9,140
|
|
|
7,706
|
|
|
18,314
|
|
|
11,952
|
|
|
Cost of professional services and other(2)
|
6,590
|
|
|
4,628
|
|
|
12,359
|
|
|
8,437
|
|
|
Total cost of revenue
|
15,730
|
|
|
12,334
|
|
|
30,673
|
|
|
20,389
|
|
|
Gross profit
|
22,054
|
|
|
20,298
|
|
|
43,590
|
|
|
39,946
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
Sales and marketing(2)
|
13,306
|
|
|
15,935
|
|
|
27,218
|
|
|
30,081
|
|
|
Research and development(2)
|
16,425
|
|
|
15,194
|
|
|
31,796
|
|
|
26,265
|
|
|
General and administrative(2)
|
6,382
|
|
|
6,766
|
|
|
13,207
|
|
|
15,764
|
|
|
Total operating expenses
|
36,113
|
|
|
37,895
|
|
|
72,221
|
|
|
72,110
|
|
|
Operating loss
|
(14,059)
|
|
|
(17,597)
|
|
|
(28,631)
|
|
|
(32,164)
|
|
|
Other income, net
|
101
|
|
|
12
|
|
|
229
|
|
|
205
|
|
|
Income before income taxes
|
(13,958)
|
|
|
(17,585)
|
|
|
(28,402)
|
|
|
(31,959)
|
|
|
Income tax benefit
|
—
|
|
|
(5,206)
|
|
|
—
|
|
|
(5,206)
|
|
|
Net loss
|
$
|
(13,958)
|
|
|
$
|
(12,379)
|
|
|
$
|
(28,402)
|
|
|
$
|
(26,753)
|
|
|
Net loss per share, basic and diluted
|
$
|
(0.10)
|
|
|
$
|
(0.09)
|
|
|
$
|
(0.21)
|
|
|
$
|
(0.23)
|
|
|
Weighted-average shares used to compute basic and diluted net loss
per share
|
136,682
|
|
|
130,537
|
|
|
135,843
|
|
|
117,807
|
|
|
_______________________
|
|
(1)
|
Prior-period information has been adjusted for the adoption of ASU No.
2014-09, Revenue from Contracts with Customers (ASC 606), which we adopted in the first quarter of
2018.
|
|
(2)
|
Includes stock-based compensation expense as follows:
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
|
|
|
(as adjusted)(1)
|
|
|
|
(as adjusted)(1)
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
Cost of subscription
|
$
|
231
|
|
|
$
|
253
|
|
|
$
|
473
|
|
|
$
|
380
|
|
|
Cost of professional services and other
|
315
|
|
|
363
|
|
|
616
|
|
|
609
|
|
|
Sales and marketing
|
1,318
|
|
|
2,441
|
|
|
2,456
|
|
|
4,595
|
|
|
Research and development
|
1,908
|
|
|
2,254
|
|
|
3,562
|
|
|
4,044
|
|
|
General and administrative
|
1,375
|
|
|
1,169
|
|
|
2,632
|
|
|
2,464
|
|
|
_______________________
|
|
(1)
|
Prior-period information has been adjusted for the adoption of ASU No.
2014-09, Revenue from Contracts with Customers (ASC 606), which we adopted in the first quarter of
2018.
|
|
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
|
|
|
(as adjusted)(1)
|
|
|
|
(as adjusted)(1)
|
|
Operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
$
|
(13,958)
|
|
|
$
|
(12,379)
|
|
|
$
|
(28,402)
|
|
|
$
|
(26,753)
|
|
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
1,713
|
|
|
2,060
|
|
|
3,573
|
|
|
2,758
|
|
|
Stock-based compensation
|
5,147
|
|
|
6,480
|
|
|
9,739
|
|
|
12,092
|
|
|
Amortization of deferred commissions
|
2,947
|
|
|
2,356
|
|
|
5,800
|
|
|
4,289
|
|
|
Amortization of deferred professional service costs
|
1,151
|
|
|
1,071
|
|
|
2,097
|
|
|
1,958
|
|
|
Lease exit and related charges
|
901
|
|
|
—
|
|
|
1,817
|
|
|
|
|
Release of deferred tax valuation allowance due to business
combination
|
—
|
|
|
(5,206)
|
|
|
—
|
|
|
(5,206)
|
|
|
Change in fair value of contingent consideration liability
|
—
|
|
|
(643)
|
|
|
—
|
|
|
(643)
|
|
|
Accretion and amortization of marketable securities
|
(135)
|
|
|
20
|
|
|
(266)
|
|
|
84
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable and other, net
|
4,944
|
|
|
(1,426)
|
|
|
(6,252)
|
|
|
(3,117)
|
|
|
Deferred commissions
|
(1,808)
|
|
|
(2,895)
|
|
|
(2,979)
|
|
|
(3,452)
|
|
|
Deferred professional service costs
|
(647)
|
|
|
(1,002)
|
|
|
(1,389)
|
|
|
(1,853)
|
|
|
Prepaid expenses and other assets
|
(2,102)
|
|
|
323
|
|
|
(1,896)
|
|
|
(859)
|
|
|
Accounts payable
|
(1,272)
|
|
|
(685)
|
|
|
511
|
|
|
(508)
|
|
|
Accrued expenses and other liabilities
|
6,398
|
|
|
4,230
|
|
|
(1,229)
|
|
|
(527)
|
|
|
Deferred revenue
|
(4,393)
|
|
|
3,582
|
|
|
(1,210)
|
|
|
6,711
|
|
|
Net cash used in operating activities
|
(1,114)
|
|
|
(4,114)
|
|
|
(20,086)
|
|
|
(15,026)
|
|
|
Investing activities:
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
(916)
|
|
|
(764)
|
|
|
(1,304)
|
|
|
(930)
|
|
|
Purchase of marketable securities
|
(13,954)
|
|
|
(15,768)
|
|
|
(23,979)
|
|
|
(31,775)
|
|
|
Maturities of marketable securities
|
10,700
|
|
|
28,938
|
|
|
26,450
|
|
|
63,737
|
|
|
Business combination, net of cash acquired
|
—
|
|
|
(2,264)
|
|
|
—
|
|
|
(2,264)
|
|
|
Net cash (used in) provided by investing activities
|
(4,170)
|
|
|
10,142
|
|
|
1,167
|
|
|
28,768
|
|
|
Financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
1,752
|
|
|
457
|
|
|
2,242
|
|
|
831
|
|
|
Payments of issuance costs related to equity
|
—
|
|
|
(119)
|
|
|
—
|
|
|
(731)
|
|
|
Net cash provided by financing activities
|
1,752
|
|
|
338
|
|
|
2,242
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash, cash equivalents and restricted
cash
|
(3,532)
|
|
|
6,366
|
|
|
(16,677)
|
|
|
13,842
|
|
|
Cash, cash equivalents and restricted cash at beginning of
period
|
49,499
|
|
|
57,342
|
|
|
62,644
|
|
|
49,866
|
|
|
Cash, cash equivalents and restricted cash at end of period
|
$
|
45,967
|
|
|
$
|
63,708
|
|
|
$
|
45,967
|
|
|
$
|
63,708
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of cash, cash equivalents and restricted cash:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
44,642
|
|
|
$
|
62,201
|
|
|
$
|
44,642
|
|
|
$
|
62,201
|
|
|
Restricted cash
|
1,325
|
|
|
1,507
|
|
|
1,325
|
|
|
1,507
|
|
|
Total cash, cash equivalents and restricted cash
|
$
|
45,967
|
|
|
$
|
63,708
|
|
|
$
|
45,967
|
|
|
$
|
63,708
|
|
|
_______________________
|
|
(1)
|
Prior-period information has been adjusted for the adoption of ASU No.
2014-09, Revenue from Contracts with Customers (ASC 606), which we adopted in the first quarter of 2018,
and ASU No. 2016-18, Statement of Cash Flows, Restricted Cash (ASC 230), which we adopted in the fourth quarter of
2017.
|
|
CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
June 30, 2018
|
|
March 31, 2018
|
|
June 30, 2017
|
|
June 30, 2018
|
|
June 30, 2017
|
|
|
|
|
|
(as adjusted)(1)
|
|
|
|
(as adjusted)(1)
|
|
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
GAAP gross profit subscription
|
$
|
25,662
|
|
|
$
|
23,815
|
|
|
$
|
22,676
|
|
|
$
|
49,477
|
|
|
$
|
44,327
|
|
|
Stock-based compensation
|
231
|
|
|
242
|
|
|
253
|
|
|
473
|
|
|
380
|
|
|
Amortization of internal-use software
|
219
|
|
|
219
|
|
|
244
|
|
|
438
|
|
|
488
|
|
|
Amortization of intangibles
|
678
|
|
|
678
|
|
|
751
|
|
|
1,356
|
|
|
751
|
|
|
Acquisition related costs
|
—
|
|
|
—
|
|
|
52
|
|
|
—
|
|
|
52
|
|
|
Non-GAAP gross profit subscription
|
$
|
26,790
|
|
|
$
|
24,954
|
|
|
$
|
23,976
|
|
|
$
|
51,744
|
|
|
$
|
45,998
|
|
|
GAAP gross margin subscription
|
73.7
|
%
|
|
72.2
|
%
|
|
74.6
|
%
|
|
73.0
|
%
|
|
78.8
|
%
|
|
Non-GAAP gross margin subscription
|
77.0
|
%
|
|
75.6
|
%
|
|
78.9
|
%
|
|
76.3
|
%
|
|
81.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
GAAP gross loss professional services
|
$
|
(3,608)
|
|
|
$
|
(2,279)
|
|
|
$
|
(2,378)
|
|
|
$
|
(5,887)
|
|
|
$
|
(4,381)
|
|
|
Stock-based compensation
|
315
|
|
|
301
|
|
|
363
|
|
|
616
|
|
|
609
|
|
|
Acquisition related costs
|
—
|
|
|
—
|
|
|
17
|
|
|
—
|
|
|
164
|
|
|
Non-GAAP gross loss professional services
|
$
|
(3,293)
|
|
|
$
|
(1,978)
|
|
|
$
|
(1,998)
|
|
|
$
|
(5,271)
|
|
|
$
|
(3,608)
|
|
|
GAAP gross margin professional services
|
(121)
|
%
|
|
(65.3)
|
%
|
|
(106)
|
%
|
|
(91.0)
|
%
|
|
(108)
|
%
|
|
Non-GAAP gross margin professional services
|
(110)
|
%
|
|
(56.7)
|
%
|
|
(88.8)
|
%
|
|
(81.4)
|
%
|
|
(89.0)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
GAAP gross profit
|
$
|
22,054
|
|
|
$
|
21,536
|
|
|
$
|
20,298
|
|
|
$
|
43,590
|
|
|
$
|
39,946
|
|
|
Impact of non-GAAP adjustments
|
1,443
|
|
|
1,440
|
|
|
1,680
|
|
|
2,883
|
|
|
2,444
|
|
|
Non-GAAP gross profit
|
$
|
23,497
|
|
|
$
|
22,976
|
|
|
$
|
21,978
|
|
|
$
|
46,473
|
|
|
$
|
42,390
|
|
|
GAAP gross margin
|
58.4
|
%
|
|
59.0
|
%
|
|
62.2
|
%
|
|
58.7
|
%
|
|
66.2
|
%
|
|
Non-GAAP gross margin
|
62.2
|
%
|
|
63.0
|
%
|
|
67.4
|
%
|
|
62.6
|
%
|
|
70.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Operating expense:
|
|
|
|
|
|
|
|
|
|
|
GAAP sales and marketing
|
$
|
13,306
|
|
|
$
|
13,912
|
|
|
$
|
15,935
|
|
|
$
|
27,218
|
|
|
$
|
30,081
|
|
|
Stock-based compensation
|
(1,318)
|
|
|
(1,138)
|
|
|
(2,441)
|
|
|
(2,456)
|
|
|
(4,595)
|
|
|
Amortization of intangibles
|
(273)
|
|
|
(448)
|
|
|
(448)
|
|
|
(721)
|
|
|
(448)
|
|
|
Acquisition related costs
|
—
|
|
|
—
|
|
|
(518)
|
|
|
—
|
|
|
(923)
|
|
|
Non-GAAP sales and marketing
|
$
|
11,715
|
|
|
$
|
12,326
|
|
|
$
|
12,528
|
|
|
$
|
24,041
|
|
|
$
|
24,115
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP research and development
|
$
|
16,425
|
|
|
$
|
15,371
|
|
|
$
|
15,194
|
|
|
$
|
31,796
|
|
|
$
|
26,265
|
|
|
Stock-based compensation
|
(1,908)
|
|
|
(1,654)
|
|
|
(2,254)
|
|
|
(3,562)
|
|
|
(4,044)
|
|
|
Acquisition related costs
|
—
|
|
|
—
|
|
|
(126)
|
|
|
—
|
|
|
(393)
|
|
|
Lease exit and related charges
|
(842)
|
|
|
(916)
|
|
|
—
|
|
|
(1,758)
|
|
|
—
|
|
|
Non-GAAP research and development
|
$
|
13,675
|
|
|
$
|
12,801
|
|
|
$
|
12,814
|
|
|
$
|
26,476
|
|
|
$
|
21,828
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP general and administrative
|
$
|
6,382
|
|
|
$
|
6,825
|
|
|
$
|
6,766
|
|
|
$
|
13,207
|
|
|
$
|
15,764
|
|
|
Stock-based compensation
|
(1,375)
|
|
|
(1,257)
|
|
|
(1,169)
|
|
|
(2,632)
|
|
|
(2,464)
|
|
|
Litigation settlement
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(250)
|
|
|
Amortization of intangibles
|
(17)
|
|
|
(17)
|
|
|
(17)
|
|
|
(34)
|
|
|
(17)
|
|
|
Change in fair value of contingent consideration liability
|
—
|
|
|
—
|
|
|
643
|
|
|
—
|
|
|
643
|
|
|
Acquisition related costs
|
—
|
|
|
—
|
|
|
(899)
|
|
|
—
|
|
|
(3,239)
|
|
|
Non-GAAP general and administrative
|
$
|
4,990
|
|
|
$
|
5,551
|
|
|
$
|
5,324
|
|
|
$
|
10,541
|
|
|
$
|
10,437
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating expense
|
$
|
36,113
|
|
|
$
|
36,108
|
|
|
$
|
37,895
|
|
|
$
|
72,221
|
|
|
$
|
72,110
|
|
|
Impact of non-GAAP adjustments
|
(5,733)
|
|
|
(5,430)
|
|
|
(7,229)
|
|
|
(11,163)
|
|
|
(15,730)
|
|
|
Non-GAAP operating expense
|
$
|
30,380
|
|
|
$
|
30,678
|
|
|
$
|
30,666
|
|
|
$
|
61,058
|
|
|
$
|
56,380
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss:
|
|
|
|
|
|
|
|
|
|
|
GAAP operating loss
|
$
|
(14,059)
|
|
|
$
|
(14,572)
|
|
|
$
|
(17,597)
|
|
|
$
|
(28,631)
|
|
|
$
|
(32,164)
|
|
|
Impact of non-GAAP adjustments
|
7,176
|
|
|
6,870
|
|
|
8,909
|
|
|
14,046
|
|
|
18,174
|
|
|
Non-GAAP operating loss
|
$
|
(6,883)
|
|
|
$
|
(7,702)
|
|
|
$
|
(8,688)
|
|
|
$
|
(14,585)
|
|
|
$
|
(13,990)
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and net loss per share:
|
|
|
|
|
|
|
|
|
|
|
GAAP net loss
|
$
|
(13,958)
|
|
|
$
|
(14,444)
|
|
|
$
|
(12,379)
|
|
|
$
|
(28,402)
|
|
|
$
|
(26,753)
|
|
|
Total pre-tax impact of non-GAAP adjustments
|
7,176
|
|
|
6,870
|
|
|
8,909
|
|
|
14,046
|
|
|
18,174
|
|
|
Income tax impact of non-GAAP adjustments
|
—
|
|
|
—
|
|
|
(5,206)
|
|
|
—
|
|
|
(5,206)
|
|
|
Non-GAAP net loss
|
$
|
(6,782)
|
|
|
$
|
(7,574)
|
|
|
$
|
(8,676)
|
|
|
$
|
(14,356)
|
|
|
$
|
(13,785)
|
|
|
GAAP net loss per share, basic and diluted
|
$
|
(0.10)
|
|
|
$
|
(0.11)
|
|
|
$
|
(0.09)
|
|
|
$
|
(0.21)
|
|
|
$
|
(0.23)
|
|
|
Non-GAAP net loss per share, basic and diluted
|
$
|
(0.05)
|
|
|
$
|
(0.06)
|
|
|
$
|
(0.07)
|
|
|
$
|
(0.11)
|
|
|
$
|
(0.12)
|
|
|
Shares used in basic and diluted net loss per share computation
|
136,682
|
|
|
134,994
|
|
|
130,537
|
|
|
135,843
|
|
|
117,807
|
|
|
_______________________
|
|
(1)
|
Prior-period information has been adjusted for the adoption of ASU No.
2014-09, Revenue from Contracts with Customers (ASC 606), which we adopted in the first quarter of
2018.
|
Castlight Media Contact:
Shannon Magill
press@castlighthealth.com
415-829-1500
Castlight Investor Contact:
Gary J. Fuges, CFA
ir@castlighthealth.com
415-829-1680
View original content with multimedia:http://www.prnewswire.com/news-releases/castlight-health-announces-second-quarter-2018-results-300688642.html
SOURCE Castlight Health, Inc.